PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Vedolizumab - Inflammatory bowel disease

PAD Profile : Vedolizumab - Inflammatory bowel disease Important

Keywords :
Crohn's disease, IBD, biologics, high cost immunomodulators, Sequential use of biologic medicines, Ulcerative Colitis, UC
Brand Names Include :
Entyvio, Entyvio SC
Important Information :
Not 1st line. Only in patients where steroids and/or TNF inhibitor not effective / appropriate

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Infusion
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

01 July 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommends the use of vedolizumab subcutaneous injection or vedolizumab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.

Please note: Dose escalation with vedolizumab is not commissioned for either presentation, by the APC collaborative organisations.

04 November 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN supports the use of Vedolizumab in the treatment of Crohn's Disease after prior therapy in line with NICE TA352. Vedolizumab will be given a RED status on the traffic light system
07 October 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

NICE TA342 - Vedolizumab for the treatment of Ulcerative Colitis was published by NICE in June 2015. PCN members recommend the use of Vedolizumab as a treatment option in line with NICE guidance and a treatment pathway has been developed with local gastroenterologists. 

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More